Johnson & Johnson Aldeyra Therapeutics, Inc. Transaction History
Johnson & Johnson
- $290 Million
- Q2 2024
A detailed history of Johnson & Johnson transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Johnson & Johnson holds 299,669 shares of ALDX stock, worth $1.65 Million. This represents 0.34% of its overall portfolio holdings.
Number of Shares
299,669
Previous 299,669
-0.0%
Holding current value
$1.65 Million
Previous $979,000
1.23%
% of portfolio
0.34%
Previous 0.21%
Shares
2 transactions
Others Institutions Holding ALDX
# of Institutions
106Shares Held
35.1MCall Options Held
153KPut Options Held
83.9K-
Perceptive Advisors LLC New York, NY9.28MShares$51 Million0.89% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.48MShares$30.1 Million12.24% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.74MShares$20.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$19.9 Million0.0% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO1.6MShares$8.8 Million0.12% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $321M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...